NCT04005755View on ClinicalTrials.gov

Maxigesic® IV Phase 3 Exposure Study

PHASE3CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

July 7, 2020

Conditions
Postoperative Pain
Interventions
DRUG

Maxigesic® IV

acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion

Trial Locations (4)

8083

Canterbury Geriatric Medical Research Trust, Christchurch

21122

Chesapeake Reserach Group, Pasadena

27514

Chapel Hill Research Group, Chapel Hill

Unknown

Southern Clinical Trials, Christchurch

Sponsors
All Listed Sponsors
lead

AFT Pharmaceuticals, Ltd.

INDUSTRY